• 1. An aptasensor for detection of potassium ions based on RecJf exonuclease mediated signal amplification
  Bidou Wang,Xifeng Chen Analyst, 2014,139, 5695-5699
• 2. An apparatus for testing water by measurement of its electrical conductivity
  Analyst, 1912,37, 538-543
• 3. An assay for the enzyme N-acetyl-β-d-glucosaminidase (NAGase) based on electrochemical detection using screen-printed carbon electrodes (SPCEs)
  R. M. Pemberton,J. P. Hart,T. T. Mottram Analyst, 2001,126, 1866-1871
• 4. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
• 5. Alumina grafted SBA-15 sustainable bifunctional catalysts for direct cross-coupling of benzylic alcohols to diarylmethanes?
  Chandran Rajendran,Govindaswamy Satishkumar,Charlotte Lang,Eric M. Gaigneaux Catal. Sci. Technol., 2020,10, 2583-2592

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Pyrazoles

Introduction to 3,5-dimethyl-1-[(pyrrolidin-2-yl)methyl]-1H-pyrazole dihydrochloride (CAS No. 1333757-63-3)

3,5-dimethyl-1-[(pyrrolidin-2-yl)methyl]-1H-pyrazole dihydrochloride, identified by its CAS number 1333757-63-3, is a compound of significant interest in the field of pharmaceutical chemistry and drug discovery. This molecule, featuring a pyrazole core substituted with dimethyl groups and a pyrrolidine-methyl side chain, has garnered attention due to its structural complexity and potential biological activity. The dihydrochloride salt form enhances its solubility, making it more amenable for various biochemical and pharmacological studies.

The pyrazole scaffold is a privileged structure in medicinal chemistry, known for its versatility in modulating biological targets. The presence of the dimethyl groups at the 3 and 5 positions introduces steric and electronic effects that can influence the compound's interactions with biological receptors. Additionally, the (pyrrolidin-2-yl)methyl moiety adds another layer of complexity, potentially enhancing binding affinity or selectivity by contributing to hydrogen bonding networks or hydrophobic interactions.

In recent years, there has been growing interest in exploring novel heterocyclic compounds for their therapeutic potential. Pyrazole derivatives have been extensively studied for their roles in anti-inflammatory, antimicrobial, and anticancer applications. The specific arrangement of substituents in 3,5-dimethyl-1-[(pyrrolidin-2-yl)methyl]-1H-pyrazole dihydrochloride suggests it may exhibit unique pharmacological properties that differentiate it from other analogs.

One of the most compelling aspects of this compound is its potential as a scaffold for further derivatization. The combination of the pyrazole ring with the pyrrolidine side chain provides multiple sites for chemical modification, allowing researchers to fine-tune its biological activity. This flexibility is particularly valuable in drug discovery pipelines where lead optimization is a critical step.

Recent studies have highlighted the importance of structure-activity relationships (SAR) in designing effective therapeutic agents. Computational modeling and experimental validation have shown that subtle changes in molecular structure can significantly impact binding affinity and pharmacokinetic properties. The dimethyl substituents in 3,5-dimethyl-1-[(pyrrolidin-2-yl)methyl]-1H-pyrazole dihydrochloride are believed to play a crucial role in determining its interaction profile with biological targets.

The dihydrochloride salt form of this compound not only improves solubility but also ensures stability under various storage conditions. This makes it an ideal candidate for both preclinical and clinical studies where consistency and reliability are paramount. The enhanced solubility also facilitates formulation development, which is a critical step in transitioning from bench research to clinical application.

From a synthetic chemistry perspective, 3,5-dimethyl-1-[(pyrrolidin-2-yl)methyl]-1H-pyrazole dihydrochloride represents an excellent example of how functional group interplay can lead to complex molecular architectures. The synthesis involves multi-step reactions that showcase the ingenuity of modern organic chemistry techniques. These synthetic strategies are not only innovative but also scalable, making it feasible to produce sufficient quantities for comprehensive biological evaluation.

The compound's potential applications extend beyond traditional therapeutic areas. Researchers are exploring its utility in modulating enzyme activity and receptor binding, which could have implications for neurodegenerative diseases and metabolic disorders. The unique structural features of 3,5-dimethyl-1-[(pyrrolidin-2-yl)methyl]-1H-pyrazole dihydrochloride make it a promising candidate for further investigation in these fields.

In conclusion, 3,5-dimethyl-1-[(pyrrolidin-2-yl)methyl]-1H-pyrazole dihydrochloride (CAS No. 1333757-63-3) is a structurally fascinating compound with significant potential in pharmaceutical research. Its complex architecture, combined with its favorable physicochemical properties, positions it as a valuable tool for drug discovery and development. As our understanding of biological systems continues to evolve, compounds like this will play an increasingly important role in addressing complex diseases and improving patient outcomes.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)